Hanmi Says Sanofi Made 'Optimal' Efpeglenatide Decision, Still Eyes 2021 Approval
Executive Summary
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.
You may also be interested in...
Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.
Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US
US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.